Platelets are a major source of excessive VEGF in Crow-Fukase syndrome, which is released during platelet aggregation and may contribute to the disease's vascular manifestations.
This is the authors' abstract. We don't add key points for this paper.
We report a marked difference in concentration of vascular endothelial growth factor (VEGF) between serum and plasma in patients with Crow-Fukase syndrome (CFS). The serum/plasma VEGF levels in 4 CFS patients were 8,634/152, 5,203/176, 3,724/127, and 868/13 pg/ml, respectively. We also showed that platelets were a major source of this VEGF and that VEGF was released during platelet aggregation by physiological stimulation. It is suggested that in CFS, local VEGF concentration is markedly elevated by aggregation of platelets containing excessive VEGF and their adhesion to vascular walls, resulting in excessive physiological activities of VEGF. Our findings provide important information for developing more effective therapeutic trials.
Answers are grounded in this paper and cite their sources.
Supports platelet origin of VEGF in Crow-Fukase syndrome; hypothesis-generating and requires confirmation before clinical consideration.
No takes yet. Share an insight, caveat, or question.
Hashiguchi et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: